Literature DB >> 8364674

Epidemiology, pathophysiology and clinical presentation of gram-negative sepsis.

M F Hazinski1, T J Iberti, N R MacIntyre, M M Parker, D Tribett, S Prion, H Chmel.   

Abstract

OBJECTIVE: To review the epidemiology and pathophysiology of gram-negative sepsis and the new consensus terminology describing the clinical signs of sepsis. DATA SOURCES: Review of the medical literature and compiled data from animal and clinical trials. PARTICIPANTS: Members of the Society of Critical Care Medicine, American College of Chest Physicians and American Association of Critical-Care Nurses with expertise on the subject of sepsis and its complications.
RESULTS: Preconference and general sessions were offered at the National Teaching Institutes of the American Association of Critical-Care Nurses, with the goal of clarifying the epidemiology, risk factors and pathophysiology of gram-negative sepsis. In addition, current terminology and new (1992) consensus terminology describing the clinical signs of sepsis were presented. Special emphasis was placed on the role of the healthcare provider in the prevention and recognition of sepsis and the role of the septic mediators in the septic cascade.
CONCLUSIONS: If the incidence of sepsis is to be reduced, the healthcare provider must be aware of the risk factors for sepsis and methods of reducing nosocomial infections. A thorough understanding of the role of mediators and consensus terminology used to describe sepsis, severe sepsis, septic shock and multiple organ dysfunction syndrome is necessary to recognize early or progressive signs of sepsis and to initiate state-of-the-art therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8364674

Source DB:  PubMed          Journal:  Am J Crit Care        ISSN: 1062-3264            Impact factor:   2.228


  3 in total

1.  [Trends in surgical intensive care. Experience in one centre over 12 years].

Authors:  C P Schneider; H Wolf; H Küchenhoff; K-W Jauch; W H Hartl
Journal:  Chirurg       Date:  2006-08       Impact factor: 0.955

2.  Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin.

Authors:  J Schimke; J Mathison; J Morgiewicz; R J Ulevitch
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

3.  Association between skin diseases and severe bacterial infections in children: case-control study.

Authors:  Robbert S A Mohammedamin; Johannes C van der Wouden; Sander Koning; Sten P Willemsen; Roos M D Bernsen; François G Schellevis; Lisette W A van Suijlekom-Smit; Bart W Koes
Journal:  BMC Fam Pract       Date:  2006-08-31       Impact factor: 2.497

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.